摘要
Future Medicinal ChemistryVol. 14, No. 15 EditorialCK1 delta inhibition: an emerging strategy to combat neurodegenerative diseasesFlavia Varano, Daniela Catarzi, Sara Calenda, Erica Vigiani & Vittoria ColottaFlavia Varano https://orcid.org/0000-0002-4342-9427Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, Sesto Fiorentino, 50019, Italy, Daniela Catarzi https://orcid.org/0000-0002-8821-928XDipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, Sesto Fiorentino, 50019, Italy, Sara CalendaDipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, Sesto Fiorentino, 50019, Italy, Erica VigianiDipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, Sesto Fiorentino, 50019, Italy & Vittoria Colotta *Author for correspondence: E-mail Address: vittoria.colotta@unifi.ithttps://orcid.org/0000-0002-9296-6819Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff, 6, Sesto Fiorentino, 50019, ItalyPublished Online:8 Jul 2022https://doi.org/10.4155/fmc-2022-0129AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: CK1 deltaCK1 delta inhibitorsneurodegenerative diseasesTPD-43 hyperphosphorylationReferences1. Catarzi D, Varano F, Vigiani E et al. Casein kinase 1 delta inhibitors as promising therapeutic agents for neurodegenerative disorders. Curr. Med. Chem. 29(27), 4698–4737 (2022)Crossref, Google Scholar2. Cheong JK, Nguyen TH, Wang H et al. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1delta/epsilon and Wnt/beta-catenin independent inhibition of mitotic spindle formation. Oncogene 30(22), 2558–2569 (2011).Crossref, Medline, CAS, Google Scholar3. Janovska P, Verner J, Kohoutek J et al. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood 131(11), 1206–1218 (2018).Crossref, Medline, CAS, Google Scholar4. Liu C, Witt L, Ianes C et al. Newly developed CK1-specific inhibitors show specifically stronger effects on CK1 mutants and colon cancer cell lines. Int. J. Mol. Sci. 20(24), 6184 (2019).Crossref, Google Scholar5. Sundaram S, Nagaraj S, Mahoney H et al. Inhibition of casein kinase 1δ/ε improves cognitive-affective behavior and reduces amyloid load in the APP-PS1 mouse model of Alzheimer's disease. Sci. Rep. 9(1), 13743 (2019).Crossref, Medline, CAS, Google Scholar6. De Lazzari F, Bisaglia M, Zordan MA, Sandrelli F. Circadian rhythm abnormalities in Parkinson's disease from humans to flies and back. Int. J. Mol. Sci. 19(12), 3911 (2018).Crossref, Google Scholar7. Chen C, Gu J, Basurto-Islas G et al. Up-regulation of CK1ε is involved in tau pathogenesis in Alzheimer's disease. Sci Rep. 7, 13478 (2017).Crossref, Medline, Google Scholar8. Li G, Yin H, Kuret J. Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J. Biol. Chem. 279(16), 15938–15945 (2004).Crossref, Medline, CAS, Google Scholar9. Adler P, Mayne J, Walker K, Ning Z, Figeys DJ. Therapeutic targeting of casein kinase 1δ/ε in an Alzheimer's disease mouse model. J. Proteome Res. 18(9), 3383–3393 (2019).Crossref, Medline, CAS, Google Scholar10. Alquezar C, Salado IG, de la Encarnacion A et al. Targeting TDP-43 phosphorylation by casein kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol. Neurodegeneration 11(1), 36 (2016).Crossref, Medline, Google Scholar11. MacKenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9(10), 995–1007 (2010).Crossref, Medline, CAS, Google Scholar12. Salado IG, Redondo M, Bello ML et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J. Med. Chem. 57(6), 2755–2772 (2014).Crossref, Medline, CAS, Google Scholar13. Martínez-González L, Rodríguez-Cueto C, Cabezudo D et al. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1 kinase inhibitor treatment. Sci. Rep. 10, 4449 (2020).Crossref, Medline, CAS, Google Scholar14. Bissaro M, Federico S, Salmaso V, Sturlese M, Spalluto G, Moro S. Targeting protein kinase CK1δ with riluzole: could it be one of the possible missing bricks to interpret its effect in the treatment of ALS from a molecular point of view? ChemMedChem 13(24), 2601–2605 (2018).Crossref, Medline, CAS, Google Scholar15. He S, Wang F, Yung KKL, Zhang S, Qu S. Effects of α‐synuclein-associated post-translational modifications in Parkinson's disease. ACS Chem. Neurosci. 12(7), 1061–1071 (2021).Crossref, Medline, CAS, Google Scholar16. Paleologou KE, Oueslati A, Shakked G et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30(9), 3184–3198 (2010).Crossref, Medline, CAS, Google Scholar17. Rubio de la Torre E, Luzo´n-Toro B, Forte-Lago I, Minguez-Castellanos A, Ferrer I, Hilfiker S. Combined kinase inhibition modulates PARKIN inactivation. Hum. Mol. Genet. 18(5), 809–923 (2009).Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 14, No. 15 Follow us on social media for the latest updates Metrics Downloaded 95 times History Received 10 June 2022 Accepted 21 June 2022 Published online 8 July 2022 Published in print August 2022 Information© 2022 Newlands PressKeywordsCK1 deltaCK1 delta inhibitorsneurodegenerative diseasesTPD-43 hyperphosphorylationFinancial & competing interests disclosureFinancial assistance for this article was received from the Italian Ministry for Universities and Research (MIUR). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download